The Seattle Genetics Medical Affairs Fellowship is a one-year, experiential program at Seattle Genetics, Inc. based in Bothell, WA. This program will prepare PharmD fellows for career opportunities in Medical Affairs by providing in-depth biopharmaceutical industry experiences.
The fellow will build Medical Affairs expertise and expand their clinical knowledge through active participation on the Medical Affairs team. During the fellowship year, the fellow will obtain an understanding of the role of Medical Affairs in the biopharmaceutical industry; develop clinical data analysis, interpretation, and communication skills; gain the ability to recognize unmet patient needs and render clinical insight for application to strategic product plans; and develop industry-appropriate professional skills. The fellow will actively participate and contribute to the Medical Information, Medical Communications, Clinical Value and Outcomes, Scientific Alliances, Medical Education, Medical Director, and Medical Science Liaison teams, while collaborating with key cross-functional groups, including Commercial, Regulatory, and Clinical Development.
The fellow will support ADCETRIS® (brentuximab vedotin), an antibody-drug conjugate (ADC) directed to the CD30 surface antigen on cells using Seattle Genetics' proprietary ADC technology. The fellow will also support Seattle Genetics’ pipeline programs, including late-stage agents enfortumab vedotin and tucatinib.
Developing skills across a broad set of Medical Affairs-related areas
Contributing to scientific communication platforms and engaging in scientific exchange
Supporting Medical Affairs at large national scientific meetings by developing scientific communication materials and graphics, with scientific engagement opportunities
Creating and executing longitudinal projects, with publication and/or presentation opportunities
Developing and delivering presentations as needed to Medical Affairs and other internal groups
Using clinical expertise and insights to inform Medical Affairs projects and initiatives
Cross-functional collaboration across Seattle Genetics, as well as interfacing with external stakeholders that may include healthcare professionals, payers, corporate partners and others
A Doctor of Pharmacy (PharmD) degree from an ACPE accredited institution
Relevant internship, clerkship, or rotational experiences
Prior clinical or industry experience is preferred
Prior oncology experience is preferred
Evidence of appropriate analytical, planning and organizational skills
Basic knowledge of the pharmaceutical industry including Product Development, Manufacturing, Regulatory, Medical Affairs, and Commercial operations
Possess good communication skills, including oral, written and presentation
Self-motivated, energetic, able to work and learn independently
Ability to thrive in a fast-paced, dynamic environment
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Wednesday, November 27th, 2019.
Letters of Recommendation are not required with application and are only required upon request.
Internal Number: 2019-630
About Seattle Genetics
Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is approved for the treatment of multiple CD30-expressing lymphomas.
Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.